source
- Analysts focus on RevMed pancreatic cancer launch and Merck data push ahead of Q3 earningsJohnson & Johnson is set to open the third quarter earnings reporting period, with analysts keen to hear about any business development news and launch execution updates. RevMed’s upcoming launch…
- Safety concerns rise as Neurocrine's Prader-Willi drug linked to deaths and hospitalizationsPatient advocates and several experts are voicing increasing alarm over the safety profile of Neurocrine Biosciences' therapy for Prader-Willi syndrome. The drug, Vykat XR, received approval 18 mo…